New developments in immunotherapy from WCLC19
A rare dry spell in Barcelona as the clouds roll in bringing yet more rain
Barcelona – While the weather for the World Congress on Lung Cancer (WCLC) has been largely gloomy with plenty of rainy spells, there’s much good news to report on the clinical front.
After yesterday’s review of the Amgen KRAS inhibitor data in G12C mutation positive patients receiving AMG 510, it’s now time to turn our attention to immunotherapy developments with several important trial readouts and in-depth analyses to discuss.
We will be posting a separate summary of the key highlights on targeted therapy, but first let’s consider what we learned on the immunotherapy front, including some of the science behind it all…
To learn more from our latest oncology conference insights and get a heads up on the details, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
